Cost considerations in the management of atrial fibrillation – impact of dronedarone

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is associated with significant morbidity and mortality. At the societal level, AF carries an enormous cost. Strategies aimed at reducing AF morbidity and mortality and containing the associated fiscal burden are of paramoun...

Descripción completa

Detalles Bibliográficos
Autores principales: Khaykin, Yaariv, Shamiss, Yana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304332/
https://www.ncbi.nlm.nih.gov/pubmed/22427725
http://dx.doi.org/10.2147/CEOR.S16675
_version_ 1782226879685591040
author Khaykin, Yaariv
Shamiss, Yana
author_facet Khaykin, Yaariv
Shamiss, Yana
author_sort Khaykin, Yaariv
collection PubMed
description Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is associated with significant morbidity and mortality. At the societal level, AF carries an enormous cost. Strategies aimed at reducing AF morbidity and mortality and containing the associated fiscal burden are of paramount importance. This review will discuss AF treatment strategies and economics, focusing on the impact of dronedarone, a novel antiarrhythmic agent.
format Online
Article
Text
id pubmed-3304332
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33043322012-03-16 Cost considerations in the management of atrial fibrillation – impact of dronedarone Khaykin, Yaariv Shamiss, Yana Clinicoecon Outcomes Res Review Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is associated with significant morbidity and mortality. At the societal level, AF carries an enormous cost. Strategies aimed at reducing AF morbidity and mortality and containing the associated fiscal burden are of paramount importance. This review will discuss AF treatment strategies and economics, focusing on the impact of dronedarone, a novel antiarrhythmic agent. Dove Medical Press 2012-03-06 /pmc/articles/PMC3304332/ /pubmed/22427725 http://dx.doi.org/10.2147/CEOR.S16675 Text en © 2012 Khaykin and Shamiss, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Khaykin, Yaariv
Shamiss, Yana
Cost considerations in the management of atrial fibrillation – impact of dronedarone
title Cost considerations in the management of atrial fibrillation – impact of dronedarone
title_full Cost considerations in the management of atrial fibrillation – impact of dronedarone
title_fullStr Cost considerations in the management of atrial fibrillation – impact of dronedarone
title_full_unstemmed Cost considerations in the management of atrial fibrillation – impact of dronedarone
title_short Cost considerations in the management of atrial fibrillation – impact of dronedarone
title_sort cost considerations in the management of atrial fibrillation – impact of dronedarone
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304332/
https://www.ncbi.nlm.nih.gov/pubmed/22427725
http://dx.doi.org/10.2147/CEOR.S16675
work_keys_str_mv AT khaykinyaariv costconsiderationsinthemanagementofatrialfibrillationimpactofdronedarone
AT shamissyana costconsiderationsinthemanagementofatrialfibrillationimpactofdronedarone

Ejemplares similares